Related Experiment Video

Updated: Aug 23, 2025

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.0K

Systemic Biomarkers and Unique Pathways in Different Phenotypes of Heart Failure with Preserved Ejection Fraction

Hao Chen1, Milorad Tesic2,3, Valentina N Nikolic4

  • 1School of Life Sciences & Institute for Biomedical Materials and Devices, Faculty of Science, University of Technology Sydney, Ultimo, NSW 2007, Australia.

Biomolecules
|October 27, 2022
PubMed

Insights

This study reveals distinct molecular signatures in acute and chronic heart failure with preserved ejection fraction (HFpEF). Researchers identified novel protein biomarkers, including LRG1, SAA1, and ITIH3, linked to microvascular inflammation for better HFpEF management.

Area of Science:

  • Cardiology
  • Proteomics
  • Biomarker Discovery

Background:

  • Heart failure with preserved ejection fraction (HFpEF) represents approximately 50% of all heart failure cases.
  • HFpEF is a complex condition with incompletely understood underlying mechanisms.

Purpose of the Study:

  • To identify unique pathogenic mechanisms in acute and chronic HFpEF and hypertrophic cardiomyopathy (HCM).
  • To discover novel protein biomarkers for improved diagnosis and management of HFpEF subtypes and HCM.

Main Methods:

  • Comprehensive, unbiased proteomic analysis using liquid chromatography-mass spectrometry.
  • Analysis of plasma samples from patients with acute HFpEF (n=8), chronic HFpEF (n=9), and HCM (n=14).
  • Comparative analysis to identify distinct molecular signatures and differentially abundant biomarkers.

Main Results:

  • Distinct molecular signatures were identified across different forms of HFpEF.
  • Differentially abundant biomarkers were predominantly associated with microvascular inflammation.
  • Candidate protein markers, including LRG1, SAA1, and ITIH3, were identified.

Conclusions:

  • This study provides the first systematic proteomic screening of plasma in HFpEF subtypes and HCM.
  • Identified biomarkers may aid in the improved management of acute and chronic HFpEF and HCM.
  • Microvascular inflammation emerges as a key pathogenic mechanism in HFpEF subtypes.

Keywords:
HCMHFpEFbiomarkersheart failureheart failure with preserved ejection fractionhypertrophic cardiomyopathyplasmaproteomics

More Related Videos

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.6K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.6K

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.7K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
31
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
164
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
262
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
43
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
27